Trial Profile

Phase II open-label trial of topical SD 101 for the treatment of chronic wounds and lesions in children with various types of epidermolysis bullosa

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 13 Jan 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Allantoin (Primary)
Indications Epidermolysis bullosa
Focus Therapeutic Use

Most Recent Events

11 Jan 2016 According to an Amicus Therapeutics media release, Allantoin has been granted FDA breakthrough therapy designation for the treatment of lesions in patients suffering with Epidermolysis-bullosa in 2013 based on results of this trial.
24 Dec 2013 New trial record
01 Jun 2013 The full data set is expected to be presented at an upcoming scientific conference, according to a Scioderm media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com